Percutaneous Coronary Intervention PCI Procedure Indications Risks And Management
medicine

Percutaneous Coronary Intervention PCI Procedure Indications Risks And Management

Percutaneous Coronary Intervention (PCI)

Definition

Percutaneous Coronary Intervention (PCI) is a minimally invasive, catheter-based procedure used to restore blood flow in narrowed or occluded coronary arteries due to atherosclerotic coronary artery disease. It is commonly called coronary angioplasty with or without stent placement.


Pathophysiology (Why PCI is needed)

  • Atherosclerosis → lipid-rich plaque forms in coronary arteries
  • Progressive luminal narrowing → myocardial ischemia
  • Plaque rupture → thrombus formation → acute coronary syndrome (ACS)
  • PCI mechanically compresses plaque, dilates the artery, and often stabilizes the lesion with a stent

Indications

Absolute / Strong Indications

  • ST-elevation myocardial infarction (STEMI) – primary PCI preferred
  • High-risk NSTEMI / Unstable angina
  • Refractory angina despite optimal medical therapy
  • Hemodynamically significant coronary stenosis (>70%, or >50% left main)

Relative Indications

  • Chronic stable angina with documented ischemia
  • In-stent restenosis
  • Cardiogenic shock due to coronary occlusion

Contraindications

Absolute

  • Patient refusal
  • No suitable vascular access (rare)

Relative

  • Severe contrast allergy
  • Advanced renal failure (risk of contrast nephropathy)
  • Diffuse disease unsuitable for stenting
  • Poor distal vessel runoff

Pre-Procedure Evaluation

  • ECG – ischemia, infarction
  • Cardiac biomarkers – troponin
  • Coronary angiography – identifies lesion
  • Echocardiography – LV function
  • Renal function tests
  • Coagulation profile

PCI Procedure (Stepwise)

  1. Vascular access – radial (preferred) or femoral artery
  2. Coronary angiography to localize lesion
  3. Guidewire passed across stenosis
  4. Balloon angioplasty (pre-dilatation)
  5. Stent deployment (DES or BMS)
  6. Post-dilatation & flow assessment (TIMI flow)
  7. Hemostasis & monitoring

Types of PCI

1. Balloon Angioplasty (PTCA)

  • Rarely used alone due to recoil & restenosis

2. Stent PCI

  • Bare Metal Stent (BMS) – higher restenosis
  • Drug-Eluting Stent (DES) – releases antiproliferative drugs (preferred)

3. Special PCI Techniques

  • Primary PCI – STEMI
  • Rescue PCI – failed thrombolysis
  • Elective PCI – stable CAD
  • Complex PCI – bifurcation, CTO, left main

Drugs Used in PCI (Complete Reference)

1. Aspirin

  • Indication: Antiplatelet backbone
  • MOA: Irreversible COX-1 inhibition → ↓ TXA₂
  • Dose:

* Loading: 150–325 mg

* Maintenance: 75–100 mg/day

  • Adverse effects: GI bleeding, dyspepsia
  • Contraindications: Active bleeding
  • Monitoring: Bleeding signs
  • Counselling: Lifelong unless contraindicated

2. P2Y12 Inhibitors (Dual Antiplatelet Therapy – DAPT)

a) Clopidogrel

  • MOA: ADP receptor (P2Y12) inhibition
  • Dose:

* Loading: 300–600 mg

* Maintenance: 75 mg/day

  • Interactions: PPIs (omeprazole)
  • Adverse effects: Bleeding, TTP (rare)

b) Ticagrelor

  • Dose: 180 mg loading → 90 mg twice daily
  • Advantages: Faster, reversible
  • Adverse effects: Dyspnea, bradycardia

c) Prasugrel

  • Contraindicated: Prior stroke/TIA, age >75

3. Anticoagulants

Unfractionated Heparin

  • MOA: Activates antithrombin III
  • Dose: 70–100 IU/kg IV
  • Monitoring: ACT
  • Risk: Bleeding, HIT

4. GP IIb/IIIa Inhibitors (Selective Use)

  • Abciximab, Eptifibatide
  • Used in high thrombus burden

Post-PCI Management

  • DAPT duration:

* DES: ≥12 months (ACS), ≥6 months (stable CAD)

  • Statins: High-intensity lifelong
  • Beta blockers (if indicated)
  • ACE inhibitors / ARBs
  • Lifestyle modification (smoking cessation, diet, exercise)

Complications of PCI

Early

  • Coronary dissection or perforation
  • Acute stent thrombosis
  • Arrhythmias
  • Bleeding / hematoma
  • Contrast-induced nephropathy

Late

  • In-stent restenosis
  • Late stent thrombosis
  • Progression of native CAD

PCI vs CABG (Brief)

| Feature | PCI | CABG |

| ------------------------ | ------------------ | ------------ |

| Invasiveness | Minimally invasive | Open surgery |

| Recovery | Fast | Longer |

| Multivessel disease | Less effective | Preferred |

| Diabetes + triple vessel | Inferior | Superior |


Prognosis

  • Excellent in STEMI when done early
  • Symptom relief in stable CAD
  • Survival benefit mainly in ACS, not routine stable angina

Interactive MCQ Quiz

Frequently Asked Questions

Percutaneous coronary intervention is a minimally invasive cardiac procedure used to open narrowed or blocked coronary arteries using a catheter-based approach, usually involving balloon angioplasty and stent placement to restore myocardial blood flow.
PCI is most strongly indicated in acute ST-elevation myocardial infarction (STEMI), high-risk non-ST elevation acute coronary syndromes, and in patients with refractory angina despite optimal medical therapy.
Coronary angiography is a diagnostic procedure used to visualize coronary arteries, whereas PCI is a therapeutic intervention performed to treat significant coronary artery stenosis identified during angiography.
Drug-eluting stents are coronary stents coated with antiproliferative drugs such as sirolimus or everolimus that reduce neointimal hyperplasia and significantly lower the risk of in-stent restenosis.
Dual antiplatelet therapy consists of aspirin plus a P2Y12 inhibitor such as clopidogrel, ticagrelor, or prasugrel, used to prevent stent thrombosis following PCI.
After drug-eluting stent implantation, DAPT is recommended for at least 12 months in acute coronary syndrome and at least 6 months in stable coronary artery disease, unless bleeding risk dictates otherwise.
Common complications include bleeding at the access site, contrast-induced nephropathy, coronary artery dissection or perforation, acute stent thrombosis, arrhythmias, and in-stent restenosis.
Radial artery access is preferred because it significantly reduces bleeding and vascular complications, allows early ambulation, and improves overall patient comfort compared to femoral access.
PCI provides a clear survival benefit in acute coronary syndromes, especially STEMI, but in stable coronary artery disease it mainly improves symptoms and quality of life rather than long-term mortality.
Premature discontinuation of dual antiplatelet therapy, stent under-expansion, high thrombus burden, diabetes mellitus, renal failure, and complex coronary lesions significantly increase the risk of stent thrombosis.